Biotech Values

[randtor]

Hello ghmm,

thanks for the link for the retail road show and ARMO few days ago. i went through the ARMO presentation couple of times. their lead IL 10 AM0010 looks pretty good and it looks like they are going through similar studies with NKTR 214 to be used in conjunction with PD1s. very good data thus far.
they are recruiting for pancreatic cancer for stage 3 but their NSCLC and RCC are phase 1s. NKTR214 is being studied for sarcoma, melanoma, rcc etc with the same PD1s.
at the proposed IPO price of 17 today, ARMO i think would have been a bargain but it opened at 28! now around 30 with market cap of close to 1B are you still interested?
with nktr market cap of 12b (they have more robust pipeline) do you think ARMO has room to go from its current price?
thanks for any input